Afatinib 20 mg

Afatinib 20 mg is an oral medication belonging to the class of tyrosine kinase inhibitors (TKIs), specifically targeting the epidermal growth factor receptor (EGFR). It is prescribed for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR gene mutations (such as exon 19 deletions or exon 21 substitution mutations).

By irreversibly blocking EGFR and other ErbB family receptors, Afatinib helps to slow down or stop the growth and spread of cancer cells. The medicine is usually taken once daily under medical supervision and may be continued as long as it shows clinical benefit.

Common side effects include diarrhea, rash, mouth sores, loss of appetite, and nail changes, while serious side effects may include lung, liver, or heart problems. Regular monitoring by a healthcare provider is essential.

Afatinib 20 mg should be taken only on a doctor’s prescription and under strict medical guidance.